Important OptumRx updates to support providers, clinical staff and patients through COVID-19.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 6, 2020 - The FDA approved Mylan’s Hulio (adalimumab-fkjp), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
